Delgado-Aros Silvia, Camilleri Michael, Castillo E Janet, Cremonini Filippo, Stephens Debra, Ferber Irene, Baxter Kari, Burton Duane, Zinsmeister Alan R
Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER) Program, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Clin Gastroenterol Hepatol. 2005 Oct;3(10):997-1006. doi: 10.1016/s1542-3565(05)00285-5.
BACKGROUND & AIMS: Altered postprandial satiation influences food intake in obesity. The aim of this study was to evaluate the contribution of gastric motor functions to intra- and postprandial symptoms in obese, otherwise healthy, people. METHODS: In a randomized, parallel-group, double-blind design, 40 obese (body mass index>30 kg/m2) healthy volunteers (n=10/group) received intravenous saline (placebo), atropine (.02 mg/kg), or erythromycin (1 or 3 mg/kg) to alter gastric volume and emptying after liquid nutrient meals, measured by validated imaging methods. The nutrient drink test assessed the volume ingested at maximum satiation, and intra- and early postprandial symptoms. Relationships between gastric motor functions, meal size, and symptoms were assessed by using multiple regression. Circulating levels of candidate upper-gut hormones involved in satiation were measured. RESULTS: Relative to placebo, atropine retarded gastric emptying and increased gastric volumes; erythromycin accelerated gastric emptying and reduced gastric volumes during fasting. Although similar maximal tolerated volumes were recorded across treatments, intra- and immediate postprandial symptoms were increased by these perturbations, particularly nausea and bloating. Upper-gut hormonal profiles generally reflected changes in gastric emptying. Regression analysis showed that fasting predrug gastric volume was a significant predictor of intra- and postprandial bloating. Change in gastric volume postdrug or postmeal did not contribute additionally to predicting intra- or postprandial symptoms. There was significant (negative) association between gastric emptying and fullness score, and significant (positive) association with hunger score 30 minutes postprandially. CONCLUSIONS: In obese individuals, fasting gastric volumes and gastric emptying, but not postprandial gastric volumes, were associated with intra- and postprandial symptoms. Understanding the determinants of gastric volume may provide insights on mechanisms controlling satiation.
背景与目的:餐后饱腹感改变会影响肥胖人群的食物摄入量。本研究旨在评估胃运动功能对肥胖但其他方面健康的人群进食期间及餐后症状的影响。 方法:采用随机、平行组、双盲设计,40名肥胖(体重指数>30kg/m²)健康志愿者(每组n = 10)在摄入液体营养餐后接受静脉注射生理盐水(安慰剂)、阿托品(0.02mg/kg)或红霉素(1或3mg/kg),以通过经验证的成像方法改变胃容量和排空情况。营养饮料测试评估最大饱腹感时摄入的量以及进食期间和进食后早期的症状。通过多元回归评估胃运动功能、进餐量和症状之间的关系。测量参与饱腹感调节的候选上消化道激素的循环水平。 结果:与安慰剂相比,阿托品延缓胃排空并增加胃容量;红霉素在禁食期间加速胃排空并减少胃容量。尽管各治疗组记录的最大耐受量相似,但这些干扰增加了进食期间和进食后即刻的症状,尤其是恶心和腹胀。上消化道激素谱总体上反映了胃排空的变化。回归分析表明,给药前空腹胃容量是进食期间和餐后腹胀的重要预测指标。给药后或进餐后胃容量的变化对预测进食期间或餐后症状没有额外贡献。胃排空与饱腹感评分之间存在显著(负)相关,与餐后30分钟的饥饿评分存在显著(正)相关。 结论:在肥胖个体中,空腹胃容量和胃排空与进食期间和餐后症状相关,而餐后胃容量则无关。了解胃容量的决定因素可能有助于深入了解控制饱腹感的机制。
Clin Gastroenterol Hepatol. 2005-10
Am J Physiol Gastrointest Liver Physiol. 2017-11-1
Gastroenterology. 2006-12
Am J Physiol Gastrointest Liver Physiol. 2002-3
Lancet Gastroenterol Hepatol. 2017-9-27
Am J Physiol Gastrointest Liver Physiol. 2004-8
Am J Physiol Gastrointest Liver Physiol. 2020-2-10
Neurogastroenterol Motil. 2020-11
Am J Physiol Gastrointest Liver Physiol. 2020-2-10
Nutrients. 2019-12-12
Am J Physiol Gastrointest Liver Physiol. 2017-11-1
Gastroenterology. 2017-5